303 related articles for article (PubMed ID: 27691967)
1. ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
Egelund EF; Isaza R; Alsultan A; Peloquin CA
J Zoo Wildl Med; 2016 Sep; 47(3):868-871. PubMed ID: 27691967
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide, and ethambutol in Asian elephants (Elephas maximus).
P Brock A; Isaza R; Egelund EF; Hunter RP; Peloquin CA
J Vet Pharmacol Ther; 2014 Oct; 37(5):472-9. PubMed ID: 24684601
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana).
Maslow JN; Mikota SK; Zhu M; Isaza R; Peddie LR; Dunker F; Peddie J; Riddle H; Peloquin CA
J Vet Pharmacol Ther; 2005 Feb; 28(1):21-7. PubMed ID: 15720511
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of rifampin in the treatment of Mycobacterium tuberculosis in Asian elephants.
Egelund EF; Isaza R; Brock AP; Alsultan A; An G; Peloquin CA
J Vet Pharmacol Ther; 2015 Apr; 38(2):137-43. PubMed ID: 25236765
[TBL] [Abstract][Full Text] [Related]
5. Effect of Genetic Variation of
Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of tuberculosis (Mycobacterium tuberculosis) in an Asian elephant (Elephas maximus) with a newborn calf.
Vogelnest L; Hulst F; Thompson P; Lyashchenko KP; Herrin KA
J Zoo Wildl Med; 2015 Mar; 46(1):77-85. PubMed ID: 25831579
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.
Rockwood N; Meintjes G; Chirehwa M; Wiesner L; McIlleron H; Wilkinson RJ; Denti P
Antimicrob Agents Chemother; 2016 Oct; 60(10):6050-9. PubMed ID: 27480859
[TBL] [Abstract][Full Text] [Related]
9. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
McIlleron H; Wash P; Burger A; Norman J; Folb PI; Smith P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1170-7. PubMed ID: 16569826
[TBL] [Abstract][Full Text] [Related]
10. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug scheduling.
Srivastava S; Sherman C; Meek C; Leff R; Gumbo T
Antimicrob Agents Chemother; 2011 Nov; 55(11):5085-9. PubMed ID: 21896907
[TBL] [Abstract][Full Text] [Related]
12. Genitourinary and pulmonary multidrug resistant Mycobacterium tuberculosis infection in an Asian elephant (Elephas maximus).
Dumonceaux GA; St Leger J; Olsen JH; Burton MS; Ashkin D; Maslow JN
J Zoo Wildl Med; 2011 Dec; 42(4):709-12. PubMed ID: 22204067
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
[TBL] [Abstract][Full Text] [Related]
14. Dose selection and pharmacokinetics of rifampin in elephants for the treatment of tuberculosis.
Peloquin CA; Maslow JN; Mikota SK; Forrest A; Dunker F; Isaza R; Peddie LR; Peddie J; Zhu M
J Vet Pharmacol Ther; 2006 Dec; 29(6):581-5. PubMed ID: 17083464
[No Abstract] [Full Text] [Related]
15. Pharmacokinetics of Antituberculosis Drugs in HIV-Positive and HIV-Negative Adults in Malawi.
van Oosterhout JJ; Dzinjalamala FK; Dimba A; Waterhouse D; Davies G; Zijlstra EE; Molyneux ME; Molyneux EM; Ward S
Antimicrob Agents Chemother; 2015 Oct; 59(10):6175-80. PubMed ID: 26248378
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
Babalik A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildizi L; Capaner E
Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
[TBL] [Abstract][Full Text] [Related]
17. Isoniazid and rifampicin concentrations in children with tuberculosis with either a daily or intermittent regimen: implications for the revised RNTCP 2012 doses in India.
Ranjalkar J; Mathew SK; Verghese VP; Bose A; Rose W; Gupta D; Fleming DH; Mathew BS
Int J Antimicrob Agents; 2018 May; 51(5):663-669. PubMed ID: 29241821
[TBL] [Abstract][Full Text] [Related]
18. In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
Pienaar E; Dartois V; Linderman JJ; Kirschner DE
BMC Syst Biol; 2015 Nov; 9():79. PubMed ID: 26578235
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci).
Auclair B; Mikota SK; Peloquin CA; Aguilar R; Maslow JN
J Zoo Wildl Med; 2002 Sep; 33(3):193-203. PubMed ID: 12462485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
